Burkholderia Pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2017

  • ID: 4426894
  • Report
  • 53 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Bavarian Nordic A/S
  • Emergent BioSolutions Inc
  • Grifols SA
  • Soligenix Inc
  • Syntiron LLC
  • MORE
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2017, provides an overview of the Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline landscape.

Burkholderia pseudomallei are a gram negative, bipolar, aerobic, motile rod-shaped soil dwelling bacterium. The bacterium can infect both animals and humans through direct contact via inhalation, ingestion, or open wounds. Signs and symptoms include fever, cough, chest pain, headache and anorexia. Risk factors include liver disease, diabetes, and thalassemia.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 8 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bavarian Nordic A/S
  • Emergent BioSolutions Inc
  • Grifols SA
  • Soligenix Inc
  • Syntiron LLC
  • MORE
Introduction

Burkholderia pseudomallei Infections (Melioidosis) - Overview

Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Burkholderia pseudomallei Infections (Melioidosis) - Companies Involved in Therapeutics Development

Bavarian Nordic A/S

Emergent BioSolutions Inc

Grifols SA

MerLion Pharmaceuticals Pte Ltd

Soligenix Inc

Syntiron LLC

Burkholderia pseudomallei Infections (Melioidosis) - Drug Profiles

ARD-3100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARD-3150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burkholderia pseudomallei vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burkholderia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EV-035 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

finafloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GC-072 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melioidosis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGX-943 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects

Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products

Burkholderia pseudomallei Infections (Melioidosis) - Product Development Milestones

Featured News & Press Releases

Jun 28, 2017: MerLion and Dstl Awarded DTRA Grant to Explore the Use of Finafloxacin against Biological Threat Agents

May 31, 2016: FDA Grants Soligenix “Fast Track” Designation for SGX943 for the Treatment of Melioidosis

Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC

Aug 14, 2014: US DTRA to fund preclinical work on Evolva’s antibiotic GC-072

Feb 21, 2014: Bavarian Nordic’s MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development

Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Bavarian Nordic A/S, H2 2017

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Emergent BioSolutions Inc, H2 2017

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Grifols SA, H2 2017

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2017

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Soligenix Inc, H2 2017

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Syntiron LLC, H2 2017

Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects, H2 2017

Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products, H2 2017

List of Figures

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Type, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bavarian Nordic A/S
  • Emergent BioSolutions Inc
  • Grifols SA
  • MerLion Pharmaceuticals Pte Ltd
  • Soligenix Inc
  • Syntiron LLC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll